PureTech Health (PRTC)

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

De PureTech Health plc American Depositary Shares (PRTC) aandelenkoers after-hours vandaag is , wat een NaN% after-hours beweging weergeeft sinds de markt laatst gesloten. De marktkapitalisatie van het bedrijf staat op $ 432,61 mln., met een dagelijks tradevolume van aandelen. De vorige slotkoers was .

Klaar om aan de slag te gaan? Volg de onderstaande stappen, of lees onze gids over hoe je PureTech Health aandelen op Kraken kunt kopen vanaf € 10.